BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Paul Matteis does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 RYTMRhythm Pharmaceuticals Inc | Buy | $78.00 | Mar 2025 | +72.2% | Hit |
 SIONSionna Therapeutics, Inc. Common Stock | Buy | $32.00 | Mar 2025 | +103.0% | Hit |
 CMPSCompass Pathways Plc | Buy | $11.00 | Feb 2025 | +66.1% | Miss |
 ANROAlto Neuroscience, Inc. | Buy | $10.00 | Nov 2024 | +139.2% | Hit |
 CTNMContineum Therapeutics, Inc. Class A Common Stock | Buy | $29.00 | Apr 2024 | −74.9% | Miss |
| ANROAlto Neuroscience, Inc. | Buy | $32.00 | Mar 2024 | −87.2% | Miss |
| ANROAlto Neuroscience, Inc. | Buy | $32.00 | Feb 2024 | −83.7% | Miss |
 ALECAlector Inc | Buy | $15.00 | Dec 2023 | −83.0% | Miss |
 VTGNVistaGen Therapeutics Inc | Buy | $12.00 | Nov 2023 | −30.8% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.